Sang Yi Sells 5,000 Shares of Zimmer Biomet (NYSE:ZBH) Stock

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) insider Sang Yi sold 5,000 shares of the company’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the transaction, the insider owned 27,251 shares of the company’s stock, valued at $2,252,022.64. This represents a 15.50% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Zimmer Biomet Stock Performance

NYSE ZBH opened at $85.11 on Thursday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95. Zimmer Biomet Holdings, Inc. has a 1 year low of $79.12 and a 1 year high of $108.29. The company has a market capitalization of $16.47 billion, a PE ratio of 22.11, a P/E/G ratio of 1.94 and a beta of 0.47. The company has a fifty day moving average of $87.68 and a two-hundred day moving average of $90.52.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The company had revenue of $2.09 billion during the quarter, compared to the consensus estimate of $2.07 billion. During the same quarter in the prior year, the firm posted $1.81 earnings per share. Zimmer Biomet’s revenue for the quarter was up 9.3% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.48 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Thursday, June 25th will be paid a dividend of $0.24 per share. The ex-dividend date is Thursday, June 25th. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. Zimmer Biomet’s dividend payout ratio is 24.94%.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Main Management ETF Advisors LLC boosted its holdings in shares of Zimmer Biomet by 1.0% in the 4th quarter. Main Management ETF Advisors LLC now owns 10,962 shares of the medical equipment provider’s stock valued at $986,000 after buying an additional 112 shares during the period. Citizens National Bank Trust Department grew its position in Zimmer Biomet by 17.6% in the 1st quarter. Citizens National Bank Trust Department now owns 941 shares of the medical equipment provider’s stock worth $85,000 after purchasing an additional 141 shares during the last quarter. Boltwood Capital Management grew its position in Zimmer Biomet by 3.9% in the 4th quarter. Boltwood Capital Management now owns 3,866 shares of the medical equipment provider’s stock worth $348,000 after purchasing an additional 144 shares during the last quarter. Independence Bank of Kentucky grew its position in Zimmer Biomet by 9.7% in the 4th quarter. Independence Bank of Kentucky now owns 1,633 shares of the medical equipment provider’s stock worth $147,000 after purchasing an additional 145 shares during the last quarter. Finally, LOM Asset Management Ltd grew its position in Zimmer Biomet by 21.5% in the 4th quarter. LOM Asset Management Ltd now owns 830 shares of the medical equipment provider’s stock worth $75,000 after purchasing an additional 147 shares during the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ZBH. Wells Fargo & Company decreased their target price on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 29th. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research note on Tuesday, February 10th. Barclays decreased their target price on shares of Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating for the company in a research note on Wednesday, April 29th. Stifel Nicolaus decreased their target price on shares of Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating for the company in a research note on Wednesday, April 29th. Finally, UBS Group reiterated a “sell” rating and set a $89.00 target price on shares of Zimmer Biomet in a research note on Wednesday, February 11th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $102.70.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.